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Abstract
Apolipoprotein E is a polymorphic and multifunctional protein with numerous roles in lipoprotein metabolism. The
three common isoforms apoE2, apoE3 and apoE4 show isoform-specific functional properties including different
susceptibilities to diseases. ApoE4 is an accepted risk factor for Alzheimer’s disease and cardiovascular disorders.
Recently, associations between apoE4 and infectious diseases have been demonstrated. This review summarises
how apoE4 may be involved in the infection incidence and associated pathologies of specific infectious diseases,
namely hepatitis C, human immunodeficiency virus disease and herpes simplex.
ApoE4 seems to be protective against chronic hepatitis C virus infection and retards fibrosis progression. In con-
trast apoE4 enhances the fusion rate of human immunodeficiency virus with target cell membranes, resulting in
accelerated cell entry and faster disease progression. Its association with human immunodeficiency virus-associated
dementia remains controversial. Regarding herpes simplex virus infection, apoE4 intensifies virus latency and is
associated with increased oxidative damage of the central nervous system, and there is some evidence that herpes
simplex virus infection in combination with the apoE4 genotype may be associated with an increased risk of Alz-
heimer’s disease. In addition to reviewing available data from human trials, evidence derived from a variety of cell
culture and animal models are considered in this review in order to provide mechanistic insights into observed
association between apoE4 genotype and viral disease infection and pathology.
Introduction
Viral diseases are a global health problem. Like many
other diseases, differences in the pathological features
and outcome of viral diseases exist, which are undoubt-
edly in part due to genetic variations in the host. Apoli-
poprotein E (apoE), in addition to being a central
mediator of lipoprotein metabolism, has an ever increas-
ing ‘repertoire’ of biological functions [1,2]. As will be
reviewed here, accumulating evidence indicates that
apoE genotype could be an important host genetic fac-
tor affecting infectious disease risk.
ApoE tissue sources and functions
The mature apoE protein results from the proteolytic
cleavage of a 317-amino acid precursor protein and con-
tains 299 amino acids with a molecular weight of
approximately 34 kDa [3]. ApoE is synthesised primarily
by the liver. It is estimated that 20-40% of total apoE is
produced by extrahepatic tissues with the brain glial
cells and macrophages expressing relatively high
amounts, with lesser amounts produced by the kidneys,
adrenals, spleen, testis and the skin [4-7]. In the circula-
tion apoE is mainly found in the lipoprotein bound
form, present in chylomicrons (CM), very low density
lipoproteins (VLDL), and high density lipoproteins
(HDL), at a plasma concentration of 20-60 mg/l [7].
The most well described role of apoE to-date is as a
regulator of multiple steps in lipid (cholesterol and tri-
glyceride) and lipoprotein metabolism, including VLDL
synthesis and secretion, the hydrolysis of VLDL to pro-
duce low density lipoproteins (LDL) and the receptor
mediated removal of triglyceride-rich lipoprotein rem-
nants (VLDL and CM remnants) by the liver [7,8]. In
addition to the systemic transport and uptake of lipo-
proteins, apoE is recognised as the primary shuttle pro-
tein for lipids which either enters the brain and central
nervous system (CNS) via the blood-brain barrier or is
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of modified lipids for excretion [10].
ApoE regulates the delivery of cholesterol and other
lipids to target cells by acting as a high affinity ligand
for multiple members of the LDL receptor family
including the LDL receptor (LDL-R), the LDL receptor-
related protein (LRP), the scavenger receptor, the VLDL
receptor, and the apoE receptor 2 [11].
In addition, apoE binds to cell surface located glycosa-
minoglycans such as heparin sulphate proteoglycans
(HSPG) [12,13] with lipoprotein uptake facilitated by
either HSPG alone or an HSPG-LRP complex [12].
ApoE genotype
The widely studied human apoE gene is located on
chromosome 19, closely linked to the apoC-I/C-II gene
complex [6,14,15]. To-date 72 individual single nucleo-
tide polymorphisms (SNPs) of the human apoE gene
have been identified [16]. The two SNPs rs429358 (C/T)
and rs7412 (C/T) [16] determine together the three
major alleles, termed Epsilon-2, Epsilon-3 and Epsilon-4.
The corresponding products of these alleles, the apoE2,
apoE3 and apoE4 protein isoforms, differ only by a sin-
gle amino acid at two residues. ApoE3 has cysteine at
residue 112 (rs429358) and arginine at residue 158
(rs7412), while apoE2 contains cysteine and apoE4 argi-
nine at both positions [17,18]. Additionally, two minor
alleles of the gene, ε1 and ε5, exist but these are present
in less than 0.1% of the population [19]. The three
major alleles are responsible for three homozygous (ε2/
ε2, ε3/ε3, ε4/ε4) and three heterozygous (ε2/ε3, ε2/ε4,
ε3/ε4) genotypes [17,18].
The amino acid substitutions affect salt bridge forma-
tion within the proteins, which ultimately impacts on
lipoprotein preference, stability of the protein and on
receptor binding activities of the isoforms [2,7] as
shown in table 1. Overall apoE4 has a comparable or
slightly higher affinity for the LDL-R relative to the
apoE3 form, with apoE2 binding with less than two per-
cent of the affinity of apoE3 [20].
ApoE genotype, blood lipid levels and risk of
cardiovascular disease and Alzheimer’s disease
The ε4 allele occurs in approximately 14% of the general
German population, but its frequency decreases signifi-
cantly with age, dropping to about 5% in centenarians
[21]. Thus, it is a major mortality factor in the elderly,
supposedly via its predisposition to both Alzheimer and
cardiovascular diseases [22,23].
The physiological and molecular mechanisms of the
associations between apoE genotype and fasting and
non-fasting lipid levels are complex, and have been
reviewed previously (see [7]). In general apoE4 carriers
have a tendency for 5-10% higher fasting total choles-
terol, LDL-cholesterol and triglyceride levels relative to
homozygote ε3/ε3 [7,24]. This tendency towards higher
lipid levels is likely to be in part responsible for the 40-
50% greater cardiovascular disease (CVD) risk in ε4c a r -
riers [25,26]; however additional mechanisms such as
differences in oxidative status and chronic inflammation
between apoE3 and apoE4 carriers may contribute to
the observed differences in the CVD risk [8].
Although the molecular basis of the pathology is
poorly understood, and likely to be in part due to apoE
genotype associated differences in brain lipid metabo-
lism, an apoE4 genotype has been highly consistently
associated with the risk of an age-related loss of cogni-
tive function, in an allele dose fashion. In a meta-analy-
sis of the AlzGene database, Bertram and colleagues
[27] reported odds ratios (OR) of Alzheimer’sd i s e a s e
(AD) in Caucasians of 4.3 (95% CI 3.3-5.5) and 15.6
(95% CI 10.9-22.5) in ε3/ε4 and ε4/ε4 subgroups relative
to the common ε3/ε3 genotype, which was consistent
with the findings of an earlier meta-analysis [28].
Additional roles of apoE as a modulator of immune
function
Lipoproteins, including apoE-containing lipoproteins,
have the ability to modulate key elements of the
immune response by either inhibiting or stimulating
antigen and mitogen induced T-lymphocyte activation
as well as proliferation [29]. ApoE interacts with sig-
nals from multiple mitogens including transferrin and
interleukin 2 (IL-2). Proliferation of both CD4 and
CD8 lymphocytes is suppressed by apoE reducing the
production of biologically active IL-2 [30]. In associa-
tion with its immunomodulatory properties [31-33],
apoE has an impact on the pathology of infectious dis-
eases. Furthermore, recent research has demonstrated
isoform-specific susceptibility to several viral infections
[2,8].
The present review article summarises the impact of
the ε4 allele on the susceptibility to specific infectious
Table 1 ApoE isoform amino acid differences and resulting chemical and physiological changes (according to Mahley
and Rall [2], Minihane et al. [7])
Isoform Amino acid 112 Amino acid 158 Relative charge Lipoprotein preference LDL receptor binding affinity
apoE2 cysteine cysteine 0 HDL low
apoE3 cysteine arginine +1 HDL high
apoE4 arginine arginine +2 VLDL, chylomicrons high
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ciency virus (HIV) disease and herpes simplex. Further-
more, ε4 allele frequencies in different populations
around the world are described. Potential mechanisms
underlying the protective or adverse effects of the apoE
isoforms in these specific virus diseases are given. We
also discuss the prevalence of the ε4 allele in different
global populations as well as the relationship between a
higher frequency in certain regions and a possible pro-
tective effect of the apoE4 isoform on commonly
encountered viral infections.
ApoE4 allele frequencies in different populations
The frequencies of the apoE alleles vary between differ-
ent ethnicities. The ε3 allele is usually the most preva-
lent, present in 50-90% of individuals, whereas ε2h a s
the lowest frequency at 0-15%, and is even absent in
some native populations. The ε4 allelic variant occurs at
a frequency of 5-30% [34].
In Europe the ε4 allele has a lower frequency in the
southern rather than in the northern countries with
continuously increasing frequencies with increasing lati-
tude. The geographical decline from ~20% in Finland
[35] to ~8% in Italy [36] and Greece [37] is likely to
contribute to the north-south gradient in the prevalence
of cardiovascular diseases [7,38,39]. In addition, ε4 tends
to be less frequent in Eastern Europe. For example,
~11% of the Polish population carry an ε4 allele [40],
while the proportion is ~14-15% in Germany and the
Netherlands [41,42]. However, differences in ε4a l l e l e
frequency are also evident within a population depend-
ing on ethnicity or geographical position. For instance,
8.5% of the individuals living in central Italy carry an ε4
allele, while the proportion is slightly lower in southern
Italy with 8.3% but only 5.3% in Sardinia, an island
approximately 250 km west of the Italian mainland [36].
Remarkably, the highest frequencies of ε4 are found in
indigenous populations and those with a recent history
of hunter gatherer lifestyle whereas long-established
agricultural communities (such as those in the Middle
East, southern Europe, in Southeast Asia and Central
America) show the lowest frequencies [38]. African
populations exhibit a two to three times higher fre-
quency than populations from Central Europe. About
37% of native Africans living in South Africa carry the
ε4 allele [43]. The highest apoE4 frequency among
populations of northern Europe and North America was
found in Inuit from the eastern part of Greenland with
23% ε4 carriers [34]. The proportion of ε4o b s e r v e di n
Aborigines (26%) is twice as high as that in Australians
of European descent (11%) [44,45]. Aceves et al.[ 4 6 ]
observed a heterogeneous ε4 frequency in Mexicans,
depending on the area’s status of urbanisation as well as
on the proportion of European gene flow, particularly
that from Spanish colonisers. In Guadalajara, the second
largest metropolitan area of Mexico with a relatively
high proportion of Spanish descent habitants, the ε4 fre-
quency was lowest at 8.4%, increased in the adjoining
state Nayarit and reached its highest frequency of 28%
in the Huichol Indians, a native Mexican population
[46].
Hepatitis C
Hepatitis C virus (HCV) infection is a major global
health problem with more than 170 million infected
people worldwide [47]. The consequences of HCV infec-
tion vary, as some newly infected individuals develop
minor or no liver damage and recover spontaneously by
clearing the virus [48], whereas approximately 85% suf-
fer from progressive chronic hepatitis C, which is the
leading cause of cirrhosis and hepatocellular carcinoma
in the Western world [49,50]. Approximately 20-25% of
HCV patients develop liver cirrhosis [51]. Accepted host
factors for chronic HCV infection and progression of
fibrosis and cirrhosis are older age at infection, male
gender, excessive consumption of alcohol, insulin resis-
tance, and the duration of infection [52,53]. In addition,
a relationship between HCV and lipid metabolism has
recently been suggested, since serum cholesterol levels
are lower in patients with chronic HCV than in appro-
priately matched controls [54].
After infection, HCV circulates in the blood in a com-
plex with lipoproteins. In the initial phase of infection,
HCV virions are mainly associated with LDL, while later
in the course of infection they are detectable in an
assembly with HDL [39,55]. Attachment to hepatocytes
is facilitated by binding of HCV envelope glycoprotein
E2 to HSPG [56] with entry site of HCV into hepato-
cytes mainly via the LDL-R [57]. Due to the fact that
both HCV and apoE bind to LDL-R and scavenger
receptor [53] and that the apoE genotype affects recep-
tor binding including a decreased number of LDL-R in
apoE4 [58], it may be hypothesised that the apoE geno-
type impacts on HCV pathology. An overview of studies
concerning the impact of apoE isoforms on HCV infec-
tion, outcome and course of disease in humans is pre-
sented in table 2.
Wozniak et al. [48] investigated the association
between apoE genotype and outcome of a HCV infec-
tion among HCV patients with chronic infection
(defined as having detectable HCV RNA in the serum)
or cleared infection (defined as presence of anti-HCV
antibodies but absence of viral RNA in the serum). The
apoE allele frequencies in the HCV infected groups were
similar to those in the control group, with no differ-
ences between the HCV RNA-positive group and the
negative individuals. In contrast, Price et al.[ 5 3 ]f o u n d
a significantly lower number of subjects homozygous for
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healthy controls, indicating a protective effect against
HCV infection of the apoE ε2/ε2 genotype [53]. In addi-
t i o n ,r i s ko fd e v e l o p i n gac h r o n i cH C Vi n f e c t i o nw a s
highest in the ε3/ε3 genotype with odds ratio of 0.39
and 0.59 for the ε2 and ε4 allele, respectively, supporting
the hypothesis that these genotypes are favouring viral
clearance [53].
The association between severity of HCV-induced
liver damage and apoE genotype was also examined
revealing significantly lower ε4 allele frequencies in
patients with severe versus mild inflammation and fibro-
sis [48] and a reduced risk of viral persistence [53] and
chronic infection [59] in apoE4 carriers, suggesting that
apoE4 protects HCV infected patients from developing
severe liver disease. However, no significant impact of
apoE genotype on non-HCV associated liver disease has
been established [48,59].
Interestingly, response to antiviral treatment was
higher in chronic HCV-patients with an ε3/ε3 genotype
than with an ε3/ε4 and ε4/ε4 genotype [60].
Possible mechanisms of the impact of apoE4 on hepatitis
C
Although several studies emphasise an impact of the
apoE genotype on the course of HCV infection as well
as on the outcome of HCV related liver damage, the
underlying mechanisms of apoE-HCV-interactions
remain to be elucidated. A summary of proposed
mechanisms is given in figure 1.
Chang et al. [49] investigated the properties of HCV
virions and the role of apoE in HCV infectivity and
virus production in an in vitro study using human hepa-
toma cell lines that stably produce infectious HCV.
Low-density HCV virions (1.08 to 1.12 g/ml) were
found to be infectious whereas the majority of HCV
RNA-containing particles emerging in higher-density
fractions (1.15 to 1.21 g/ml) were poorly or not infec-
tious. Additionally, infectious low-density HCV virions
were rich in apoE, and levels of apoE and HCV RNA in
infectious fractions were positively correlated. A short
interfering RNA (siRNA)-mediated knockdown of apoE
expression reduced apoE secretion and caused an appar-
ent dose-dependent suppression of HCV virion produc-
tion in the cells. However, the amount of HCV RNA-
containing particles was not significantly affected by an
apoE overexpression indicating that the level of apoE
expression is not a limiting factor for HCV replication.
Chang et al. [49] suggested that apoE knockdown-asso-
ciated reduction of HCV RNA-containing particles was
not related to an inhibition of HCV release but was
more likely due to the blockage of apoE dependent
HCV virion assembly. Taken together these results
demonstrate that in vitro apoE is required for the pro-
duction of low-density HCV particles as well as for their
infectivity. However, mechanisms of apoE genotype-spe-
cific effects on HCV life cycle remain uncertain [49].
Since HCV particles are supposed to enter target cells
via LDL-R [57] and thus, compete with apoE containing
lipoproteins for receptor binding [1], it was hypothesised
that the already established decreased LDL-R expression
in ε4v s .ε3 carriers [58] could diminish hepatic HCV
uptake and spread between hepatocytes [48].
In summary apoE seems to be involved in the HCV life
cycle. Although the mechanisms are yet poorly under-
stood, the apoE4 isoform appears to have a HCV-specific
protective effect on liver disease with available data indi-
cating that the outcome of chronic HCV infection is bet-
ter among ε4 carriers due to slower fibrosis progression.
Limited evidence indicates that the ε4 allele may also be
associated with poor viral treatment response.
HIV infection and HIV-associated dementia
Infection with HIV and progression to the acquired
immunodeficiency syndrome (AIDS) is a growing global
health problem. At the end of 2007, the Joint United
Nations Programme on HIV/AIDS estimated that 33.2
million people were living with HIV, 95% of them in
developing countries [61].
Table 2 Effects of an apoE4 genotype on hepatitis C virus (HCV) infection and outcome in humans
Reference Subjects and profile Parameter Outcome
Wozniak et al. 2002 [48] 156 HCV patients: 111 chronically infected and 45 with cleared
infection, and 104 non-HCV infected patients
- risk of HCV infection
- risk of severe liver disease caused
by chronic HCV infection
- risk of non-HCV associated liver
diseases and extent of disease
ε2=ε3=ε4
non-ε4>ε4
ε2=ε3=ε4
Mueller et al. 2003
[60]
506 chronically infected HCV patients response to antiviral treatment of
HCV infection
non-ε4>ε4
Price et al. 2006 [53] 420 Caucasian HCV patients: 312 chronically infected and 108 with
cleared infection, and 288 healthy controls
risk of chronic HCV infection ε3>ε4>ε2
Mueller et al. 2007
[59]
701 HCV patients chronically infected, 523 healthy controls, and
283 patients with non-HCV associated liver diseases
- risk of chronic HCV infection
- risk of severe non-HCV associated
liver disease
non-ε4>ε4
ε4 = non- ε4
HCV: hepatitis C virus
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glia, in particular CD4
+ T-lymphocyte cells [62]. These
cells are infected by HSPG mediated virus attachment
[63] followed by binding of HIV envelope glycoproteins
to the CD4 receptor. The resulting conformational
change allows the envelope glycoproteins to bind to one
of the two possible co-receptors CCR5 and CXCR4 [62].
In preparation of cell entry, HIV fuses with the target
cell membrane, which requires cholesterol in HIV parti-
cles and lipid rafts (membrane microdomains enriched
in certain lipids, cholesterol and proteins) [64,65]. The
infected cells synthesise HIV proteins including the HIV
transactivator protein (Tat) that activates viral and cellu-
lar gene expression [66]. Newly assembled virus particles
are transported to the cell surface and released by
exocytotic fusion with the plasma membrane for further
cell infection [67].
The acute phase of HIV infection is characterised by
extensive and rapid loss of CD4
+ cells due to apoptosis
that persists into the chronic phase of infection. Plasma
levels of CD4
+ cells are partially reconstituted after the
first infection period, but then decrease continuously.
Counting CD4
+ cells is therefore a key measure to
assess progression of HIV disease [68]. Antiretroviral
therapy is currently the best known way to protect
mucosal tissue and to prevent microbial translocation
and chronic activation of the immune system. It reduces
the plasma levels of HIV RNA and induces a greater
reconstitution of CD4
+ cells [68]. A low CD4
+ cell
count is an independent risk factor for HIV-associated
Figure 1 Potential mechanisms of the impact of apoE4 on viral treatment response, fibrosis progression in recurrent HCV infection as
well as protection against HCV associated severe liver damage. LDL: low density lipoprotein, LDL-R: low density lipoprotein receptor, HCV:
hepatitis C virus
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third of HIV infected adults. HIV-associated dementia is
accompanied by microglial cell activation, astrocytosis,
decreased synaptic and dendritic density and selective
neuronal loss [70]. Symptomatic parallels between HIV-
associated dementia and AD have been previously
reported [69,71]. HIV infection of microglia, neurons
and astrocytes in associated with stimulation of tumor
necrosis factor a (TNF-a)a n di n d u c i b l en i t r i co x i d e
synthase (iNOS) expression in the neighbouring unin-
fected cells [72], which have also been observed in AD
[69]. In vitro,T N F - a substantially enhances the tran-
scription of HIV in chronically infected mononuclear
cells [73-75]. The pathogenesis of HIV and AIDS is
therefore directly connected with the activation state of
the host immune system [76].
Given that cholesterol is a crucial component of the
HIV envelope and essential for viral entry and assembly
[64,77,78] and that apoE is essential for cholesterol
transport [10], along with being a mediator of brain
inflammatory process [79], it may be hypothesised that
the apoE genotype influences HIV-induced effects on
neurological functions. Table 3 summarises studies on
the effect of apoE4 on HIV pathogenesis and related dis-
orders in humans.
In a study by Corder et al. [69] HIV infected patients
were evaluated every six months during a period of five
years. Although non-significant, a tendency towards
decreased CD4
+ cell count was evident in ε4 carriers. In
addition, a highly significant difference of frequencies of
neurological symptoms was evident with an incidence of
30% in ε4 carriers and 15% in non-ε4 carriers. Periph-
eral neuropathy was also more common among indivi-
duals carrying ε4 [69].
An acceleration of the HIV disease course by apoE4
has also been observed in the Hawaii Aging with HIV
Cohort. Those HIV patients who possessed at least
one ε4 allele tended to have a faster self-reported HIV
progression with 8.3 compared to 10.5 years. However,
CD4
+ cell count as an indicator of disease progression
as well as plasma HIV RNA and intracellular HIV
DNA levels were not affected by apoE4 [71]. Further
classification of the cohort revealed that the ε4 allele
was more frequent in the younger group (<40 years,
37%), than in the older group (>50 years, 23%) indicat-
ing that ε4 may influence survival. In contrast to the
younger individuals, in the older cohort an apoE4 gen-
otype was associated with an increased risk of HIV-
associated dementia after controlling for age and dia-
betes status [80]. These findings highlight the possibi-
lity of an impact of age on the ability of apoE
genotype to module the risk of developing HIV-asso-
ciated dementia [71].
However further larger studies have failed to confirm
this impact of apoE genotype on HIV-associated demen-
tia prevalence [63,81]. Dunlop et al. [81] did not observe
any differences in allele distribution among AIDS
patients with clinical signs of dementia or histological
signs of encephalitis relative to patients free of these
clinical symptoms. The impact of a homozygous ε4/ε4
genotype was not determinable due to the low presence
among the study participants [81]. Consistent with the
Dunlop findings Burt et al. [63] did not observe any sig-
nificant impact of genotype on the risk of acquiring HIV
infection and HIV-associated dementia. However there
was some evidence to suggest that apoE genotype influ-
enced the course of infection, with homozygosity for the
ε4 allele associated with an accelerated course of disease.
The impact of ε4/ε4 genotype on disease progression
was not influenced by CD4
+ cell count. In contrast, the
effect of ε4/ε4 genotype on the course of HIV was mini-
mised after adjustment for the steady-state viral load,
indicating that the extent of viral replication is affected
by apoE genotype.
Furthermore, Burt et al.d e m o n s t r a t e di na nin vitro
model that the cell entry of HIV strains is apoE isoform
Table 3 Effects of apoE4 genotype on HIV course of disease and HIV-associated dementia in humans
Reference Subjects and profile Parameter Outcome
Corder et al. 1998
[69]
44 HIV infected patients - risk of HIV-associated dementia
- risk of peripheral neuropathy in HIV
infection
ε4 > non-ε4
ε4 > non-ε4
Dunlop et al. 1997
[81]
132 AIDS patients and postmortem samples of
hippocampus
risk of HIV-associated dementia and
encephalitis
ε2=ε3=ε4
Burt et al. 2008
[63]
1,267 HIV-positive patients and 1,132 healthy
controls
- risk of acquiring HIV infection
- acceleration of HIV disease progression
- increase of steady-state viral load
- risk of HIV-associated dementia
ε2=ε3=ε4
ε4/ε4>ε3/non-ε3 and ε3/ε3
ε4/ε4>ε4/non-ε4 > non-ε4/
non-ε4
ε4 = non-ε4
Valcour et al. 2004
[80]
222 HIV-positive patients of the Hawaii Aging with
HIV Cohort
- ε4 allele frequency
- risk of HIV-associated dementia
younger cohort > older cohort
ε4 > non-ε4 within the older
cohort
AIDS: acquired immunodeficiency syndrome, HIV: human immunodeficiency virus
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in the presence of apoE4 compared with apoE3, which
may in part explain the higher infection rate in ε4c a r -
riers [63].
In summary, available evidence indicates that the ε4
allele has detrimental effects on the course of HIV infec-
tions. It has been associated with higher steady-state
viral load and faster disease progression due to acceler-
ated virus entry in ε4 carriers. However, CD4
+ cell
count does not appear to be significantly affected by the
apoE genotype. The correlation between apoE4 and
HIV-associated dementia is possibly age dependent, but
remains controversial and needs to be clarified by
further studies.
Possible mechanisms of the impact of apoE4 on HIV
infection and HIV-associated dementia
Although the risk of acquiring HIV infection is indepen-
dent of the apoE allelic variant, carriage of ε4 is asso-
ciated with an increased steady-state viral load and a
faster progression of HIV disease. Furthermore, an
increased cell entry of HIV in vitro strains was discov-
ered in the presence of apoE4 compared to the presence
of apoE3 [63].
One possible underlying mechanism may be an impact
of apoE genotype on LDL-R and HSPG binding activ-
ities which would directly impact on cellular HIV parti-
cle uptake (figure 2). ApoE found on the virus’ envelope
may facilitate virus entry by targeting HIV virions to the
LDL-R expressing cells [82]. ApoE4’sm o d e s t l yh i g h e r
receptor binding affinity may promote virus contact to
target cells and hence increases HIV cell entry and as a
consequence disease progression.
Dobson et al. demonstrated in an in vitro experiment
that short apoE fragments containing the heparin-bind-
ing domain, namely residues 142 to 147, have antiviral
activity against HIV infection. This effect possibly results
from blockade of HIV attachment to HSPG (figure 2)
[83]. The observation of lower HSPG mediated VLDL
Figure 2 Potential mechanisms for apoE4 mediated faster progression of HIV disease. LDL: low density lipoprotein, LDL-R: low density
lipoprotein receptor, HIV: human immunodeficiency virus, HSPG: heparin sulphate proteoglycans.
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lipoproteins in a variety of cells cell lines [84] suggests
that in apoE4 individuals lower competition is likely to
be associated with accelerated HSPG mediated HIV cell
entry.
In addition, the amphipathic helical domain of apoli-
poproteins shows homology with the viral fusogenic
domains [63,83,85] and therefore Burt et al.[ 6 3 ]p r o -
posed that the amphipathic helical domain of apoE may
act as a HIV fusion inhibitor by binding to the HIV
membrane protein gp41 and blocking either the forma-
tion or the function of the HIV N-terminal fusogenic
domain. Based on the observation that apoE4, compared
to apoE3, enhances HIV fusion and cell entry, apoE4
seems to be a less efficient fusion inhibitor [63]. The dif-
ferential antiviral activity of apoE isoforms may be due
to either these structural characteristics that make the
amphipathic helical domain of apoE4 less accessible to
HIV fusion domains or to isoform-specific changes in
inhibitory domain activity [63] (figure 2).
Cholesterol is a crucial component of the HIV envel-
ope as well as of cholesterol rich lipid rafts which are
essential for both, HIV entry and release [64,77,78].
Consequently, depletion of cholesterol from either the
cell membrane or the HIV envelope results in a loss of
infectivity [64,77]. ApoE4 genotype is associated with
higher LDL levels and might therefore support an accu-
mulation of plasma membrane raft-associated choles-
terol and an increase of lipid raft formation, resulting in
an enhancement of HIV infection cycle including HIV
fusion and cell entry as well as assembly of HIV virions
and its release [63]. In addition, the increased LDL levels
in ε4 carriers may promote the formation of HIV envel-
opes and therewith of HIV virions, presumably resulting
in higher viral load and faster disease progression as
summarised in figure 2.
The validity and relative importance of the above
mentioned mechanisms proposed to underlie the impact
of apoE genotype on HIV cell entry and viral load
requires further investigation.
The neurotoxic protein Tat has been proposed to be
involved in the development of HIV-associated dementia
[66,70]. Tat is actively released mainly from HIV
infected macrophages, astrocytes and microglia and is
taken up by uninfected cells [66,86-90]. It is supposed
to interact with neuronal membranes inducing oxidative
stress. A higher Tat-induced oxidative damage was evi-
dent in wild-type relative to apoE-knockout mice attrib-
uted to a competition between apoE and Tat for LRP-R
uptake [66]. In the presence of murine apoE, the contact
time of Tat with cell membranes is prolonged, increas-
ing the degree of Tat-induced oxidative damage. In cor-
tical neurones Tat-induced toxicity was lower in
presence of lipid-associated human apoE3 as compared
to apoE4 indicating less oxidative damage in membrane
lipids and proteins [66].
Figure 3 schematically summarises possible mechan-
isms underlying apoE genotype-HIV-associated demen-
tia-interactions.
Herpes simplex
Herpes simplex is a neurotropic infectious disease
caused by a herpes simplex virus (HSV) which is an
enveloped double stranded DNA virus [91] classified
into two subspecies. Herpes simplex virus type 1 (HSV-
1) contributes to the pathogenesis of numerous clinical
conditions in humans with herpes labialis, also known
as cold scores or fever blisters, being the symptom most
often recognised [1], while herpes simplex virus type 2
(HSV-2) usually causes genital infections [92]. Seropre-
valences of HSV-1 and HSV-2 infections increase with
age. HSV-1 is spread more widely than HSV-2 [92] and
one of the most commonly encountered pathogens with
a prevalence of 40-50% among adolescents and 60-90%
among adult populations [93].
HSV-1 DNA is detectable in brain regions mainly
affected in AD [94]. Though HSV-1 has been described
as reducing overall synthesis of most host cell proteins,
it has been shown to trigger cellular b-amyloid produc-
tion and accumulation, which is a major hallmark of
AD [95]. Interestingly, b-amyloid peptide and glycopro-
tein B of HSV-1 viral envelopes show significant amino
acid sequence homology [96].
There are few studies investigating a potential associa-
tion between HSV-1 infection, apoE4 genotype and
development of AD with inconsistent outcomes (sum-
marised in table 4).
The susceptibility to HSV-1 infection was not affected
by apoE genotype [97]. In an elderly cohort, apoE ε4
allele frequency was found to be highest among HSV-1-
positive AD patients compared to HSV-1-negative AD
patients and to non-AD patients indicating a several
t i m e sh i g h e rA Dr i s kf o rs u b j e c t sc a r r y i n gε4 allele with
HSV-1 infection than for non-ε4 carriers [98]. Thus, the
HSV-1 infection alone shows no effect, but in combina-
tion with the apoE4 genotype the risk of AD increases
apparently in the elderly [99]. Increasing age may facili-
tate viral entry into the CNS by declined immune or
barrier function since HSV-1 was not detected in brains
of younger people [98]. In addition to the increased sus-
ceptibility of the central nervous system the apoE4 gen-
otype was also reported to increase the risk of HSV-1
induced cold scores in the peripheral nervous tissue
[98].
In contrast in a prospective population based study of
512 non-demented elderly subjects a significant associa-
tion between primary HSV-1 infection or reactivation
(IgM-positive status) and development of AD was
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oped dementia including 77 cases of AD. However, no
interactions between the apoE genotype and IgM-posi-
tive status on the risk of AD could be observed,
although the relatively small number of ε4 carriers with
HSV-1 infection has to be considered [100]. Neverthe-
less, in a previous study the combination of HSV-1
infection and apoE4 genotype did also not reveal any
significant effect on the prevalence of AD [97].
Studies in transgenic apoE mice provide further evi-
dence of an interaction between the apoE genotype and
HSV-1 infection. Burgos et al. [101] analysed the invol-
vement of different apoE isoforms in HSV-1 access to
the CNS during the acute phase of infection. Thus, 14-
week-old female apoE3 and apoE4 transgenic mice were
inoculated with HSV-1 and the infection status of sev-
eral tissues was analysed six days after inoculation.
ApoE isoform dependent differences in the viral load in
the CNS and certain brain regions were observed.
Figure 3 Possible mechanisms of the impact of apoE4 on increased neurodegeneration and HIV-associated dementia. Tat: transactivator
protein, LRP: low density lipoprotein receptor-related protein, HIV: human immunodeficiency virus.
Table 4 Effects of apoE4 genotype on herpes simplex virus (HSV)-1 infection and outcome in humans
Reference Subjects and profile Parameter Outcome
Itzhaki et al.
1997 [98]
46 Caucasian AD patients and 44 Caucasian
non-AD elderly controls
risk of AD highest in ε4 carriers positive for HSV-1
40 Caucasian cold-score sufferers and 33
age-matched Caucasian healthy controls
risk of HSV-1-induced cold-
scores
ε4 > non-ε4
Itabashi et
al. 1997 [99]
46 elderly AD patients and 23 age-matched
controls without confirmed neuropsychiatric
disease
HSV and risk of AD latent HSV infection alone is not an independent risk
factor for AD, the combination of ε4 and HSV infection
increases the risk
Beffert et al.
1998 [97]
73 elderly AD patients and 33 non-AD
controls
- susceptibility to HSV-1
infection in brain
- risk of AD
ε4 = non-ε4
no effect of HSV-1 and ε4 combined
Letenneur et
al. 2008
[100]
512 French individuals in a population
based cohort study
apoE genotype and HSV
immunoglobulin status as risk
factors for AD
no interactions between apoE status and HSV
immunoglobulin status on risk of AD
HSV: herpes simplex virus, AD: Alzheimer’s disease, CNS: central nervous system
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levels in the spinal cord and in all regions of the brain.
HSV-1 levels in the cortex, cerebellum and ventricles of
apoE3 transgenic mice were undetectable, while apoE4
transgenic mice showed significantly higher levels of
HSV-1 in these brain regions. However, no significant
differences were detected in the blood and the adrenal
glands. These data show that apoE4 facilitates migration
of HSV-1 from the adrenal gland to the brain ten times
more efficiently than apoE3 [101].
In a further study, the influence of the apoE profile
on levels of latent HSV-1 DNA was investigated in the
same rodent model [94]. Since HSV-1 is present in a
latent state four weeks after inoculation, viral DNA
concentration was determined five weeks after infec-
tion, when latency was assured. The highest virus
loads were found in the nervous system, including
spinal cord, brain and trigeminal ganglia, and in the
blood possibly derived from the trigeminal ganglia.
Therefore, it has been suggested that a high viral load
is accompanied with establishment of HSV-1 latency in
the respective tissues. Wild-type mice showed signifi-
cantly higher concentrations of HSV-1 than apoE-
knockout mice in the nervous tissue, adrenal glands
and ovaries but similar concentrations in the blood. In
comparison to apoE3 mice, apoE4 mice had higher
levels of latent HSV-1 DNA, except for the adrenal
glands and the blood. In the apoE4 mice HSV-1 was
detected in all brain regions analysed, while in apoE3
mice HSV-1 was only detectable in the midbrain.
Latent HSV-1 DNA levels in the nervous system were
twelve times higher in the presence of apoE4 com-
pared to apoE3 [94]. Burgos et al. [94] suggested that
apoE4 may increase the risk of developing AD by
increasing latent HSV-1 viral load in the nervous sys-
tem. The ability to cause damage may depend on the
exact location, the immune status of the host, and the
amount of virus (in which apoE genotype status could
play an important role) [94].
In conclusion, current literature indicates that apoE4
intensifies the susceptibility for HSV-1 related herpes
labialis as well as the neuroinvasiveness of HSV-1 com-
pared to other apoE variants and that the combination
of apoE4 and HSV-1 may lead to a higher risk of AD,
than either factor in isolation. However inconsistencies
exist in the literature, which is likely to be in large part
due to the lack of the statistical power of the human
studies conducted to date.
Possible mechanisms of the impact of apoE4 on herpes
simplex (Figure 4)
Similar to HCV and HIV, HSV competes with apoE for
receptor binding [1]. In addition HSV attachment to the
target cells is facilitated by HSPG located on the cell’s
surface [102]. Therefore differences in apoE-HSPG
associations are also likely to impact on the cellular
HSV uptake as proposed by Itzhaki and Wozniak [1].
Furthermore, lipid rafts are involved in HSV entry as
well [65]. As discussed for HIV, the higher levels of
LDL present in ε4 carriers possibly support an accumu-
lation of cholesterol in these specialised membrane
domains and increases their formation [63]. This would
enhance virus entry and therewith the chance for HSV
to establish latency.
HSV-1 infection of the murine nervous system is asso-
ciated with up-regulated iNOS expression as well as
raised levels of pro-inflammatory cytokines [103,104]
which undoubtedly play a central role in the neuronal
injury associated with the viral infection. Given the
observation of increased oxidative stress, inflammatory
cytokine production and nitric oxide production asso-
ciated with an apoE4 genotype [8,105-107] and the less
efficient neuronal repair described in E4 carriers [69],
this considerable overlap between the pathological
effects of an apoE4 genotype and the neuronal impact
of the HSV provides a likely mechanism to explain the
observation of increased AD risk in E4 carriers asso-
ciated with HSV infection.
Conclusion
This review provides an overview of the so far available
data on the involvement of the apoE genotype in the
pathogenesis of specific virus diseases. It is conceivable
that due to its beneficial effects in certain harmful infec-
tious diseases, as demonstrated for hepatitis C, the ε4
allele may not have been eliminated by evolutionary
selection. In such a way there exists a geographical
north-south gradient in Italy with a higher number of
HCV infections in the south of Italy [108] parallel to the
inverse geographical gradient in apoE4 genotype fre-
quency being lowest in southern Italy [36]. However,
substantial studies are needed to correlate geographical
differences and ethnic origins with the incidence of
these virus infections.
The mechanisms of HCV, HIV and HSV infection
bear resemblance to each other, since all three viruses
compete with apoE for cell attachment and receptor
binding. Therefore it would be interesting to investigate
whether other types of viruses share the same mechan-
ism and whether their cell entry is affected by the apoE
genotype. This could contribute to our understanding of
the apparent paradox that apoE4 competes efficiently
with HCV for receptor binding but is less efficient in
inhibiting the binding of HIV and HSV to the receptors.
Since the detailed mechanisms of the impact of
apoE4 on the virus cell entry, the infection cycle and
the virus-induced disorders are not completely under-
stood, further experimental and clinical studies are
needed.
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may influence the pathogenesis of infectious virus dis-
eases may open up novel strategies to develop persona-
lised antiviral treatments depending on the individual’s
apoE genotype.
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